Abstract
Black Americans are under-represented in cancer clinical trials because of myriad factors. Minority under-representation in clinical trials likely contributes to the disparate cancer outcomes among minorities and the poor. This Commentary, in light of a clinical trial that was prematurely terminated because of poor accrual of black men, discusses strategies to identify and overcome barriers to enrollment for this particularly vulnerable population.